Latest filings (excl ownership)
S-8
Registration of securities for employees
10 May 24
10-Q
2024 Q1
Quarterly report
10 May 24
8-K
Results of Operations and Financial Condition
9 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
16 Apr 24
10-K
2023 FY
Annual report
12 Mar 24
8-K
Results of Operations and Financial Condition
12 Mar 24
8-K
Clearside Biomedical Announces Pricing of $15 Million Registered
8 Feb 24
424B5
Prospectus supplement for primary offering
8 Feb 24
8-K
Entry into a Material Definitive Agreement
1 Feb 24
8-K
Entry into a Material Definitive Agreement
28 Dec 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
13 Nov 23
8-K
Entry into a Material Definitive Agreement
3 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
29 Sep 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Results of Operations and Financial Condition
14 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
22 Jun 23
EFFECT
Notice of effectiveness
22 May 23
CORRESP
Correspondence with SEC
17 May 23
UPLOAD
Letter from SEC
17 May 23
S-3
Shelf registration
12 May 23
8-K
Entry into a Material Definitive Agreement
12 May 23
S-8
Registration of securities for employees
12 May 23
10-Q
2023 Q1
Quarterly report
12 May 23
8-K
Results of Operations and Financial Condition
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
8-K
Other Events
18 Apr 23
10-K
2022 FY
Annual report
14 Mar 23
8-K
Results of Operations and Financial Condition
9 Mar 23
8-K
Departure of Directors or Certain Officers
21 Feb 23
8-K
Departure of Directors or Certain Officers
6 Feb 23
8-K
Results of Operations and Financial Condition
2 Feb 23
8-K
Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update
9 Nov 22
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
Latest ownership filings
4
BENJAMIN R YERXA
15 May 24
4
Anthony S Gibney
19 Apr 24
4
Anthony S Gibney
16 Apr 24
3
Anthony S Gibney
16 Apr 24
4
Ngai Hang Victor Chong
20 Mar 24
4
Ngai Hang Victor Chong
18 Mar 24
3
Ngai Hang Victor Chong
18 Mar 24
4
BRADFORD T WHITMORE
9 Feb 24
4
GEORGE M LASEZKAY
19 Jan 24
4
Charles A. Deignan
19 Jan 24
144
Notice of proposed sale of securities
19 Jan 24
144
Notice of proposed sale of securities
19 Jan 24
4
BRADFORD T WHITMORE
1 Nov 23
SC 13G/A
WHITMORE BRADFORD T
1 Nov 23
3
BRADFORD T WHITMORE
1 Nov 23
4
Nancy J Hutson
4 Oct 23
4
Clay Thorp
25 Sep 23
4
William D. Humphries
22 Sep 23
4
Charles A. Deignan
20 Sep 23
4
GEORGE M LASEZKAY
20 Sep 23
4
Charles A. Deignan
13 Sep 23
4
Clay Thorp
23 Jun 23
4
Richard Croarkin
23 Jun 23
4
JEFFREY L EDWARDS
23 Jun 23
4
William D. Humphries
23 Jun 23
4
Nancy J Hutson
23 Jun 23
4
CHRISTY L SHAFFER
23 Jun 23
4
BENJAMIN R YERXA
23 Jun 23
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 23
SC 13G/A
Carmignac Gestion
13 Feb 23
4
Thomas Ciulla
20 Jan 23
4
GEORGE M LASEZKAY
20 Jan 23
4
Charles A. Deignan
20 Jan 23
4
Thomas Ciulla
11 Jan 23
4
GEORGE M LASEZKAY
6 Jan 23
4
Charles A. Deignan
6 Jan 23
4
Thomas Ciulla
6 Jan 23
SC 13D/A
Hatteras Venture Advisors III, LLC
4 Jan 23
SC 13G/A
WHITMORE BRADFORD T
4 Jan 23
4
Clay Thorp
21 Dec 22